Facilitating Access to Approved Medication
Get Access To Dexrazoxane for Injection
Dexrazoxane for Injection
- Brand Name – On Request
- API – Ribociclib
- Packaging – 21 Tablets
- Strength – 200 mg
- Manufacturer Name – Novartis Pharma
What is Dexrazoxane for Injection used for?
Ribociclib Tablet is a cyclin-dependent kinase inhibitor, indicated to use with the combination of the aromatase inhibitor to treat HR-Positive and HER2-Negative advanced as well as metastatic breast cancer. This FDA approved medication was developed by Novartis.
Note: (For Prescribing Information Approved Drugs, see)
- The Food and Drug Administration (FDA), USA.
- The European Medicines Agency (EMA).
Disclaimer
All Trademarks and Brands that appear on website belong to their respective owners does not lay and claim on them we only provide Information. We are NOT ONLINE store and We do not sell Narcotics and Sedatives. Dexrazoxane for Injection is a pharmaceutical drug To access this medicine, a prescription of your treating doctor is necessary.. Following Information meant for Wholesalers, Suppliers, Exporters, Doctors, Comparator Supplies, Hospitals, Generic, Brand, Corporate Sourcing, reseller, and Pharmacies.
Lucknow Speciality Pharma, Lucknow, India
Lucnow Speciality Pharma is registered in Lucknow, India. Registration Number : AAKFL2122J1ZB Under GST Act
Branch Offices in India : Lucknow | Agra | Jaipur | Varanasi | New Delhi
2nd Floor, 203-A, Felix Square, Golf City, Gomti Nagar, Lucknow, Uttar Pradesh 226030
Mobile :+91 97600 14849 / 9555306364
WhatsApp :+91 97600 14849 / 9555306364
Dexrazoxane :- Uses & Approval
Dexrazoxane has been used to protect the heart against the cardiotoxic side effects of chemotherapeutic drugs such as anthracyclines, such as daunorubicin or doxorubicin or other chemotherapeutic agents.
The United States Food and Drug Administration has also approved a dexrazoxane for use as a treatment of extravasation resulting from IV anthracycline chemotherapy. Extravasation is an adverse event in which chemotherapies containing anthracylines leak out of the blood vessel and necrotize the surrounding tissue.
On July 19, 2017, based on evaluation of the currently available data the European Commission issued an EU-wide legally binding decision to implement the recommendations of the Committee for Medicinal Products for Human Use (CHMP) on dexrazoxane and lifted its 2011-contraindication for primary prevention of anthracycline-induced cardiotoxicity with dexrazoxane in children and adolescents where high doses (≥ 300 mg/m3) of anthracyclines are anticipated.
NEWS / UPDATES
Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association
Addition of Sorafenib to Chemotherapy May Improve Outcomes in Pediatric HAR FLT3/ITD1+ AML
Breast Cancer and the Cardiovascular Disease: A Narrative Review